News for Jazz Pharmaceuticals plc (JAZZ)

Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.

First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a bispecific 2 + 1 T cel…

EverQuote, Jazz Pharmaceuticals, The Progressive, Sony and NatWest have been highlighted in this Screen of The Week article.

**media[550677]**

VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline o…

Total Annual Revenue: Over $4 billion for 2024.Fourth Quarter Revenue: Nearly $1.1 billion, highest ever for the company.Adjusted Net Income (Non-GAAP): $1.37

Feb 25, 2025 / 09:30PM GMTOperator Thank you for standing by. My name is Jeannie, and I will be your conference operator today. At this time, I would like to we

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ETCompany ParticipantsJeff Macdonald - Executive Director,...

The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with their 2024 Q4 earnings call.

Jazz (JAZZ) delivered earnings and revenue surprises of 13.99% and 2.57%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals PLC (JAZZ) announced its financial results for the full year and fourth quarter of 2024, reporting record total revenues of $4.1 billion, a

PR NewswireDUBLIN, Feb. 25, 2025 ”“ Record total revenues of $4.1 billion in 2024 and $1.1 billion in 4Q24 ”“”“ Xywav® and Epidiolex® revenues grew 16

Revenue: Achieved record total revenues of $4.1 billion for 2024, surpassing the annual estimate of $4.04 billion.Quarterly Revenue: Fourth quarter revenue rea

**media[549431]**

Jazz Pharmaceuticals PLC (JAZZ), a leading global biopharmaceutical company, announced on February 20, 2025, that it will participate in TD Cowen's 45th Annual

VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) —

On December 31, 2024, Vestal Point Capital, LP (Trades, Portfolio) executed a significant transaction involving Applied Therapeutics Inc (APLT). The firm added

Vestal Point Capital, LP (Trades, Portfolio), a prominent investment firm, recently made a significant adjustment to its holdings in uniQure NV. On December 31,

On December 31, 2024, Vestal Point Capital, LP (Trades, Portfolio), a prominent investment firm, executed a noteworthy transaction by acquiring an additional 2,